Dr. Lillian W. Chiang is a co-founder and is currently the President and CEO of Evrys Bio, an innovator biotech developing broad-spectrum small-molecule antivirals. Lillian is a science-driven serial entrepreneur who has focused on small molecules and built from scratch state-of-the-art technologies, drug discovery teams, and businesses at Millennium Pharmaceuticals, Purdue Pharma, Aestus Therapeutics, and Kadmon Corporation. Along the way she has co-authored numerous papers across multiple disciplines including bacterial genetics, neurobiology, bioinformatics, genomics, clinical translation, and virology. She currently serves as a member of the board of directors for the Hepatitis B Foundation. B.S., Life Science, Massachusetts Institute of Technology; PhD, Bacteriology, University of Wisconsin; Postdoc, Pharmacology and Neurobiology, Stanford University; MBA, Wharton, University of Pennsylvania.
Dr. Lillian W. Chiang is a co-founder and is currently the President and CEO of Evrys Bio, an innovator biotech developing broad-spectrum small-molecule antivirals. Lillian is a science-driven serial entrepreneur who has focused on small molecules and built from scratch state-of-the-art technologies, drug discovery teams, and businesses at Millennium Pharmaceuticals, Purdue Pharma, Aestus Therapeutics, and Kadmon Corporation. Along the way she has co-authored numerous papers across multiple disciplines including bacterial genetics, neurobiology, bioinformatics, genomics, clinical translation, and virology. She currently serves as a member of the board of directors for the Hepatitis B Foundation. B.S., Life Science, Massachusetts Institute of Technology; PhD, Bacteriology, University of Wisconsin; Postdoc, Pharmacology and Neurobiology, Stanford University; MBA, Wharton, University of Pennsylvania.